<html><head>
    <meta http-equiv="Content-Security-Policy" content="default-src 'none'; script-src http: https: 'unsafe-inline'; style-src http: https: 'unsafe-inline' ; img-src http: https: data:; font-src http: https:; connect-src http: https:; media-src http: https:; object-src 'none'; child-src 'none'; frame-src 'none'">
    <script type="text/javascript">
      

      // Initialize sandbox
      (function () {
        function blockMethod (name) {
          return () => console.error("Ignored call to '" + name + "()'.")
        }

        window['alert'] = blockMethod('alert'); window['confirm'] = blockMethod('confirm'); window['print'] = blockMethod('print'); window['prompt'] = blockMethod('prompt');
        delete window['Worker']; window['Worker'] = undefined; delete window['indexedDB']; window['indexedDB'] = undefined;

        let _navigator = {};
        for (let key in navigator) {
          const prop = navigator[key];
          if (typeof prop !== 'object' && typeof prop !== 'function') {
            _navigator[key] = prop;
          }
        }
        delete window.navigator;
        window.navigator = _navigator;
      })();
    </script>
    
  </head>
  <body>
    
<style type="text/css">
.tftable {font-size:14px;color:#333333;width:100%;border-width: 1px;border-color: #87ceeb;border-collapse: collapse;}
.tftable th {font-size:18px;background-color:#87ceeb;border-width: 1px;padding: 8px;border-style: solid;border-color: #87ceeb;text-align:left;}
.tftable tr {background-color:#ffffff;}
.tftable td {font-size:14px;border-width: 1px;padding: 8px;border-style: solid;border-color: #87ceeb;}
.tftable tr:hover {background-color:#e0ffff;}
</style>

<table class="tftable" border="1">
<tbody><tr>
<th>ID</th>
<th>Name</th>
<th>Code</th>
</tr>

<tr>
<td>1</td>
<td>Congenital anomaly of aortic arch branch</td>
<td>LA8B.24</td>
</tr>
<tr>
<td>2</td>
<td>Paratyphoid fever A</td>
<td>1A08&amp;XN1K5</td>
</tr>
<tr>
<td>3</td>
<td>Vitamin A deficiency, unspecified</td>
<td>5B55.Z</td>
</tr>
<tr>
<td>4</td>
<td>Atrial fibrillation, unspecified</td>
<td>BC81.3Z</td>
</tr>
<tr>
<td>5</td>
<td>Hypervitaminosis A</td>
<td>5B90.0</td>
</tr>
<tr>
<td>6</td>
<td>Other specified adrenocortical insufficiency</td>
<td>5A74.Y</td>
</tr>
<tr>
<td>7</td>
<td>Other specified hereditary sensory or autonomic neuropathy</td>
<td>8C21.Y</td>
</tr>
<tr>
<td>8</td>
<td>Duplications of the short arm of chromosome 17</td>
<td>LD41.G1</td>
</tr>
<tr>
<td>9</td>
<td>Oculocutaneous albinism</td>
<td>EC23.20</td>
</tr>
<tr>
<td>10</td>
<td>Gangliosidosis</td>
<td>5C56.00</td>
</tr>
<tr>
<td>11</td>
<td>Primary hypercholesterolaemia</td>
<td>5C80.00</td>
</tr>
<tr>
<td>12</td>
<td>Interrupted aortic arch</td>
<td>LA8B.22</td>
</tr>
<tr>
<td>13</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>14</td>
<td>Dystonia-plus</td>
<td>8A02.11</td>
</tr>
<tr>
<td>15</td>
<td>Mucopolysaccharidosis type 2</td>
<td>5C56.31</td>
</tr>
<tr>
<td>16</td>
<td>Other specified structural developmental anomaly of heart or great vessels</td>
<td>LA8Y</td>
</tr>
<tr>
<td>17</td>
<td>Other specified mucopolysaccharidosis</td>
<td>5C56.3Y</td>
</tr>
<tr>
<td>18</td>
<td>Vitamin A deficiency with other specified manifestations</td>
<td>5B55.Y</td>
</tr>
<tr>
<td>19</td>
<td>Mucopolysaccharidosis type 4</td>
<td>5C56.32</td>
</tr>
<tr>
<td>20</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>21</td>
<td>Certain specified disorders of arteries or arterioles</td>
<td>BD52</td>
</tr>
<tr>
<td>22</td>
<td>Disorders of nucleotide metabolism</td>
<td>5C55.2</td>
</tr>
<tr>
<td>23</td>
<td>Insulin-resistance syndromes</td>
<td>5A44</td>
</tr>
<tr>
<td>24</td>
<td>Testicular hypofunction</td>
<td>5A81.1</td>
</tr>
<tr>
<td>25</td>
<td>Secondary syphilis of skin or mucous membranes</td>
<td>1A61.3</td>
</tr>
<tr>
<td>26</td>
<td>Chronic kidney disease, stage 3a</td>
<td>GB61.2</td>
</tr>
<tr>
<td>27</td>
<td>Other specified problems associated with upbringing</td>
<td>QE9Y</td>
</tr>
<tr>
<td>28</td>
<td>Extravasation of urine</td>
<td>MF50.5</td>
</tr>
<tr>
<td>29</td>
<td>Fabry disease</td>
<td>5C56.01</td>
</tr>
<tr>
<td>30</td>
<td>Lichen sclerosus, unspecified</td>
<td>EB60.Z</td>
</tr>
<tr>
<td>31</td>
<td>Structural device failure, as mode of injury or harm</td>
<td>PL12.0</td>
</tr>
<tr>
<td>32</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>33</td>
<td>Problem of unspecified body part</td>
<td>ME86.Z</td>
</tr>
<tr>
<td>34</td>
<td>Hypersomnia associated with a mental disorder</td>
<td>7A25</td>
</tr>
<tr>
<td>35</td>
<td>Female infertility without specification whether primary or secondary</td>
<td>GA31.Z</td>
</tr>
<tr>
<td>36</td>
<td>Hereditary skin peeling</td>
<td>EC20.1</td>
</tr>
<tr>
<td>37</td>
<td>Other specified arthrogryposis syndromes</td>
<td>LD26.4Y</td>
</tr>
<tr>
<td>38</td>
<td>Acute monoblastic or monocytic leukaemia</td>
<td>2A60.34</td>
</tr>
<tr>
<td>39</td>
<td>Acute hepatitis A</td>
<td>1E50.0</td>
</tr>
<tr>
<td>40</td>
<td>Hyperprolactinaemia</td>
<td>5A60.1</td>
</tr>
<tr>
<td>41</td>
<td>Waardenburg-Shah syndrome</td>
<td>LD2H.3</td>
</tr>
<tr>
<td>42</td>
<td>Vertical gaze palsy</td>
<td>9C83.01</td>
</tr>
<tr>
<td>43</td>
<td>Other specified sphingolipidosis</td>
<td>5C56.0Y</td>
</tr>
<tr>
<td>44</td>
<td>Congenital anomaly of a ventricle or the ventricular septum, unspecified</td>
<td>LA88.Z</td>
</tr>
<tr>
<td>45</td>
<td>Shigellosis due to Shigella dysenteriae</td>
<td>1A02&amp;XN285</td>
</tr>
<tr>
<td>46</td>
<td>Syndromes with lissencephaly as a major feature</td>
<td>LD20.1</td>
</tr>
<tr>
<td>47</td>
<td>Follicular keratosis due to vitamin A deficiency</td>
<td>5B55.Y/2F21.Y</td>
</tr>
<tr>
<td>48</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
<td>NE60</td>
</tr>
<tr>
<td>49</td>
<td>Metachromatic leukodystrophy</td>
<td>5C56.02</td>
</tr>
<tr>
<td>50</td>
<td>Syndromes with vascular anomalies as a major feature</td>
<td>LD23</td>
</tr>
<tr>
<td>51</td>
<td>Paratyphoid fever B</td>
<td>1A08&amp;XN322</td>
</tr>
<tr>
<td>52</td>
<td>Unspecified undernutrition</td>
<td>5B7Z</td>
</tr>
<tr>
<td>53</td>
<td>Chronic hepatitis B, unspecified</td>
<td>1E51.0Z</td>
</tr>
<tr>
<td>54</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>55</td>
<td>Other specified hereditary sensory or autonomic neuropathy</td>
<td>8C21.Y</td>
</tr>
<tr>
<td>56</td>
<td>Encephalitis due to herpes simplex virus</td>
<td>1F00.21</td>
</tr>
<tr>
<td>57</td>
<td>Oculocutaneous albinism</td>
<td>EC23.20</td>
</tr>
<tr>
<td>58</td>
<td>Vitamin B2 deficiency</td>
<td>5B5B</td>
</tr>
<tr>
<td>59</td>
<td>B lymphoblastic leukaemia or lymphoma, not elsewhere classified</td>
<td>2A70.0</td>
</tr>
<tr>
<td>60</td>
<td>Vitamin B1 deficiency, unspecified</td>
<td>5B5A.Z</td>
</tr>
<tr>
<td>61</td>
<td>Hereditary fructose intolerance</td>
<td>5C51.50</td>
</tr>
<tr>
<td>62</td>
<td>Interrupted aortic arch</td>
<td>LA8B.22</td>
</tr>
<tr>
<td>63</td>
<td>Vitamin B3 deficiency, unspecified</td>
<td>5B5C.Z</td>
</tr>
<tr>
<td>64</td>
<td>Congenital muscular dystrophy</td>
<td>8C70.6</td>
</tr>
<tr>
<td>65</td>
<td>Mature B-cell neoplasms, unspecified</td>
<td>2A8Z</td>
</tr>
<tr>
<td>66</td>
<td>Gangliosidosis</td>
<td>5C56.00</td>
</tr>
<tr>
<td>67</td>
<td>Vitamin B6 deficiency</td>
<td>5B5D</td>
</tr>
<tr>
<td>68</td>
<td>Vitamin B12 deficiency</td>
<td>5B5F</td>
</tr>
<tr>
<td>69</td>
<td>Autosomal dominant hereditary spastic paraplegia</td>
<td>8B44.00</td>
</tr>
<tr>
<td>70</td>
<td>Other specified vitamin B1 deficiency</td>
<td>5B5A.Y</td>
</tr>
<tr>
<td>71</td>
<td>Mucopolysaccharidosis type 2</td>
<td>5C56.31</td>
</tr>
<tr>
<td>72</td>
<td>Other specified vitamin B3 deficiency</td>
<td>5B5C.Y</td>
</tr>
<tr>
<td>73</td>
<td>Other specified mucopolysaccharidosis</td>
<td>5C56.3Y</td>
</tr>
<tr>
<td>74</td>
<td>Mucopolysaccharidosis type 4</td>
<td>5C56.32</td>
</tr>
<tr>
<td>75</td>
<td>Human leukocyte antigen positive</td>
<td>MA14.18</td>
</tr>
<tr>
<td>76</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>77</td>
<td>Disorders of nucleotide metabolism</td>
<td>5C55.2</td>
</tr>
<tr>
<td>78</td>
<td>Insulin-resistance syndromes</td>
<td>5A44</td>
</tr>
<tr>
<td>79</td>
<td>Hereditary agammaglobulinaemia with profoundly reduced or absent B cells</td>
<td>4A01.00</td>
</tr>
<tr>
<td>80</td>
<td>Malignant lymphoma of B cell type, not elsewhere classified</td>
<td>2A86.0</td>
</tr>
<tr>
<td>81</td>
<td>Chronic kidney disease, stage 3b</td>
<td>GB61.3</td>
</tr>
<tr>
<td>82</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>83</td>
<td>Japanese encephalitis</td>
<td>1C85</td>
</tr>
<tr>
<td>84</td>
<td>Hereditary skin peeling</td>
<td>EC20.1</td>
</tr>
<tr>
<td>85</td>
<td>Other specified arthrogryposis syndromes</td>
<td>LD26.4Y</td>
</tr>
<tr>
<td>86</td>
<td>Acute monoblastic or monocytic leukaemia</td>
<td>2A60.34</td>
</tr>
<tr>
<td>87</td>
<td>Acute hepatitis B</td>
<td>1E50.1</td>
</tr>
<tr>
<td>88</td>
<td>Megavitamin-B6 syndrome</td>
<td>5B90.3</td>
</tr>
<tr>
<td>89</td>
<td>Other specified sphingolipidosis</td>
<td>5C56.0Y</td>
</tr>
<tr>
<td>90</td>
<td>Shigellosis due to Shigella flexneri</td>
<td>1A02&amp;XN7Y2</td>
</tr>
<tr>
<td>91</td>
<td>Genetic susceptibility to particular pathogens</td>
<td>4A00.2</td>
</tr>
<tr>
<td>92</td>
<td>Mucopolysaccharidosis type 6</td>
<td>5C56.33</td>
</tr>
<tr>
<td>93</td>
<td>Human leukocyte antigen negative</td>
<td>MA14.17</td>
</tr>
<tr>
<td>94</td>
<td>Other specified immunodeficiencies with predominantly antibody defects</td>
<td>4A01.0Y</td>
</tr>
<tr>
<td>95</td>
<td>Other specified chronic hepatitis B</td>
<td>1E51.0Y</td>
</tr>
<tr>
<td>96</td>
<td>Immunodeficiency with factor B deficiency</td>
<td>4A00.12</td>
</tr>
<tr>
<td>97</td>
<td>Haemophilia B</td>
<td>3B11.0</td>
</tr>
<tr>
<td>98</td>
<td>Immune dysregulation syndromes presenting primarily with lymphoproliferation</td>
<td>4A01.22</td>
</tr>
<tr>
<td>99</td>
<td>Diabetes mellitus due to other genetic syndromes</td>
<td>5A13.6</td>
</tr>
<tr>
<td>100</td>
<td>Female Genital Mutilation Type 2b</td>
<td>GC51.11</td>
</tr>
<tr>
<td>101</td>
<td>Other specified syndromic craniosynostoses</td>
<td>LD24.GY</td>
</tr>
<tr>
<td>102</td>
<td>B lymphoblastic leukaemia or lymphoma, not elsewhere classified</td>
<td>2A70.0</td>
</tr>
<tr>
<td>103</td>
<td>Cerebral vasoconstriction syndromes</td>
<td>8B22.2</td>
</tr>
<tr>
<td>104</td>
<td>Paratyphoid fever C</td>
<td>1A08&amp;XN5TR</td>
</tr>
<tr>
<td>105</td>
<td>Irritable bowel syndrome, constipation predominant</td>
<td>DD91.00</td>
</tr>
<tr>
<td>106</td>
<td>Haemoglobin C disease</td>
<td>3A51.5</td>
</tr>
<tr>
<td>107</td>
<td>Vitamin C deficiency, unspecified</td>
<td>5B56.Z</td>
</tr>
<tr>
<td>108</td>
<td>Crimean-Congo haemorrhagic fever</td>
<td>1D49</td>
</tr>
<tr>
<td>109</td>
<td>Multiple system atrophy, Cerebellar type</td>
<td>8D87.00</td>
</tr>
<tr>
<td>110</td>
<td>Congenital pulmonary airway malformations</td>
<td>LA75.4</td>
</tr>
<tr>
<td>111</td>
<td>Compound heterozygous sickling disorders without crisis</td>
<td>3A51.3</td>
</tr>
<tr>
<td>112</td>
<td>Female Genital Mutilation, unspecified</td>
<td>GC51.Z</td>
</tr>
<tr>
<td>113</td>
<td>Chronic hepatitis C</td>
<td>1E51.1</td>
</tr>
<tr>
<td>114</td>
<td>Other specified sickle cell disorders or other haemoglobinopathies</td>
<td>3A51.Y</td>
</tr>
<tr>
<td>115</td>
<td>Other specified hereditary sensory or autonomic neuropathy</td>
<td>8C21.Y</td>
</tr>
<tr>
<td>116</td>
<td>Other specified vitamin C deficiency</td>
<td>5B56.Y</td>
</tr>
<tr>
<td>117</td>
<td>Hereditary sensory and autonomic neuropathy type I</td>
<td>8C21.0</td>
</tr>
<tr>
<td>118</td>
<td>Interrupted aortic arch</td>
<td>LA8B.22</td>
</tr>
<tr>
<td>119</td>
<td>Congenital corneal opacity</td>
<td>LA11.5</td>
</tr>
<tr>
<td>120</td>
<td>Diffuse palmoplantar keratodermas</td>
<td>EC20.30</td>
</tr>
<tr>
<td>121</td>
<td>Endothelial corneal dystrophy</td>
<td>9A70.0</td>
</tr>
<tr>
<td>122</td>
<td>Fracture of second cervical vertebra, unspecified</td>
<td>NA22.1Z</td>
</tr>
<tr>
<td>123</td>
<td>Fracture of first cervical vertebra, unspecified</td>
<td>NA22.0Z</td>
</tr>
<tr>
<td>124</td>
<td>Other specified mucopolysaccharidosis</td>
<td>5C56.3Y</td>
</tr>
<tr>
<td>125</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>126</td>
<td>Fracture of third cervical vertebra</td>
<td>NA22.2&amp;XA2W05</td>
</tr>
<tr>
<td>127</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>128</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>129</td>
<td>Compound heterozygous sickling disorders with crisis</td>
<td>3A51.4</td>
</tr>
<tr>
<td>130</td>
<td>Hereditary angioedema</td>
<td>4A00.14</td>
</tr>
<tr>
<td>131</td>
<td>Disorders of nucleotide metabolism</td>
<td>5C55.2</td>
</tr>
<tr>
<td>132</td>
<td>Fracture of fourth cervical vertebra</td>
<td>NA22.2&amp;XA3RE9</td>
</tr>
<tr>
<td>133</td>
<td>Fracture of fifth cervical vertebra</td>
<td>NA22.2&amp;XA9C12</td>
</tr>
<tr>
<td>134</td>
<td>Other specified sphingolipidosis</td>
<td>5C56.0Y</td>
</tr>
<tr>
<td>135</td>
<td>Fracture of sixth cervical vertebra</td>
<td>NA22.2&amp;XA5S79</td>
</tr>
<tr>
<td>136</td>
<td>Other specified malignant neoplasms of thyroid gland</td>
<td>2D10.Y</td>
</tr>
<tr>
<td>137</td>
<td>Fracture of seventh cervical vertebra</td>
<td>NA22.2&amp;XA34U8</td>
</tr>
<tr>
<td>138</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>139</td>
<td>St Louis encephalitis</td>
<td>1C86</td>
</tr>
<tr>
<td>140</td>
<td>Immunodeficiency with an early component of complement deficiency</td>
<td>4A00.10</td>
</tr>
<tr>
<td>141</td>
<td>Acute hepatitis C</td>
<td>1E50.2</td>
</tr>
<tr>
<td>142</td>
<td>Other specified defects in the complement system</td>
<td>4A00.1Y</td>
</tr>
<tr>
<td>143</td>
<td>Shigellosis due to Shigella boydii</td>
<td>1A02&amp;XN8RN</td>
</tr>
<tr>
<td>144</td>
<td>Immunodeficiency with a late component of complement deficiency</td>
<td>4A00.11</td>
</tr>
<tr>
<td>145</td>
<td>Atlanto-axial dislocation</td>
<td>NA23.11</td>
</tr>
<tr>
<td>146</td>
<td>Scorbutic anaemia</td>
<td>3A03.2</td>
</tr>
<tr>
<td>147</td>
<td>Hypersecretion of calcitonin</td>
<td>5A04</td>
</tr>
<tr>
<td>148</td>
<td>Haemophilia C</td>
<td>3B13</td>
</tr>
<tr>
<td>149</td>
<td>Female Genital Mutilation Type 2c</td>
<td>GC51.12</td>
</tr>
<tr>
<td>150</td>
<td>Intestinal infections due to Clostridioides difficile</td>
<td>1A04</td>
</tr>
<tr>
<td>151</td>
<td>Graft-versus-host disease, unspecified</td>
<td>4B24.Z</td>
</tr>
<tr>
<td>152</td>
<td>Irritable bowel syndrome, diarrhoea predominant</td>
<td>DD91.01</td>
</tr>
<tr>
<td>153</td>
<td>Haemoglobin D disease</td>
<td>3A51.6</td>
</tr>
<tr>
<td>154</td>
<td>Vitamin D deficiency, unspecified</td>
<td>5B57.Z</td>
</tr>
<tr>
<td>155</td>
<td>Hypervitaminosis D</td>
<td>5B90.2</td>
</tr>
<tr>
<td>156</td>
<td>Presence of cardiac resynchronization therapy defibrillator</td>
<td>QB50.01</td>
</tr>
<tr>
<td>157</td>
<td>Complete trisomy 13</td>
<td>LD40.1</td>
</tr>
<tr>
<td>158</td>
<td>Other specified vitamin D deficiency</td>
<td>5B57.Y</td>
</tr>
<tr>
<td>159</td>
<td>Acute graft-versus-host disease</td>
<td>4B24.0</td>
</tr>
<tr>
<td>160</td>
<td>Chronic graft-versus-host disease</td>
<td>4B24.1</td>
</tr>
<tr>
<td>161</td>
<td>Hereditary sensory and autonomic neuropathy type I</td>
<td>8C21.0</td>
</tr>
<tr>
<td>162</td>
<td>Congenital muscular dystrophy</td>
<td>8C70.6</td>
</tr>
<tr>
<td>163</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>164</td>
<td>Neuronal ceroid lipofuscinosis</td>
<td>5C56.1</td>
</tr>
<tr>
<td>165</td>
<td>Other specified porphyrias</td>
<td>5C58.1Y</td>
</tr>
<tr>
<td>166</td>
<td>Abnormal ventricular relationships</td>
<td>LA81</td>
</tr>
<tr>
<td>167</td>
<td>Other specified mucopolysaccharidosis</td>
<td>5C56.3Y</td>
</tr>
<tr>
<td>168</td>
<td>Chronic hepatitis D</td>
<td>1E51.2</td>
</tr>
<tr>
<td>169</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>170</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>171</td>
<td>Vitamin D deficiency rickets</td>
<td>5B57.0</td>
</tr>
<tr>
<td>172</td>
<td>Other specified disorders of glycine metabolism</td>
<td>5C50.7Y</td>
</tr>
<tr>
<td>173</td>
<td>Maternal care for red cell antibodies</td>
<td>JA86.0</td>
</tr>
<tr>
<td>174</td>
<td>Disorders of vitamin D metabolism or transport, unspecified</td>
<td>5C63.2Z</td>
</tr>
<tr>
<td>175</td>
<td>Hypocalcaemic vitamin D dependent rickets</td>
<td>5C63.20</td>
</tr>
<tr>
<td>176</td>
<td>Mucopolysaccharidosis type 4</td>
<td>5C56.32</td>
</tr>
<tr>
<td>177</td>
<td>Hypophosphataemic rickets</td>
<td>5C63.22</td>
</tr>
<tr>
<td>178</td>
<td>Acute hepatitis D</td>
<td>1E50.3</td>
</tr>
<tr>
<td>179</td>
<td>Cerebral organic aciduria</td>
<td>5C50.E1</td>
</tr>
<tr>
<td>180</td>
<td>Other specified disorders of vitamin D metabolism or transport</td>
<td>5C63.2Y</td>
</tr>
<tr>
<td>181</td>
<td>Other specified disorders of glyoxylate metabolism</td>
<td>5C51.2Y</td>
</tr>
<tr>
<td>182</td>
<td>Other specified structural developmental anomaly of heart or great vessels</td>
<td>LA8Y</td>
</tr>
<tr>
<td>183</td>
<td>Shigellosis due to Shigella sonnei</td>
<td>1A02&amp;XN9M9</td>
</tr>
<tr>
<td>184</td>
<td>Primary haemophagocytic lymphohistiocytosis</td>
<td>4A01.23</td>
</tr>
<tr>
<td>185</td>
<td>Low vitamin D in chronic kidney disease</td>
<td>GB61.Z/5B57.Z</td>
</tr>
<tr>
<td>186</td>
<td>Syndromes with lissencephaly as a major feature</td>
<td>LD20.1</td>
</tr>
<tr>
<td>187</td>
<td>Complex brachydactylies</td>
<td>LD26.1</td>
</tr>
<tr>
<td>188</td>
<td>Disorders of peroxisomal alpha-, beta- or omega-oxidation</td>
<td>5C57.1</td>
</tr>
<tr>
<td>189</td>
<td>Vitamin D deficiency osteomalacia</td>
<td>5B57.1</td>
</tr>
<tr>
<td>190</td>
<td>Immunodeficiency with factor D anomaly</td>
<td>4A00.13</td>
</tr>
<tr>
<td>191</td>
<td>Oligosaccharidosis</td>
<td>5C56.21</td>
</tr>
<tr>
<td>192</td>
<td>Spondyloepiphyseal or spondyloepimetaphyseal dysplasias</td>
<td>LD24.3</td>
</tr>
<tr>
<td>193</td>
<td>Hypertriglyceridaemia</td>
<td>5C80.1</td>
</tr>
<tr>
<td>194</td>
<td>Hypocalcaemic vitamin D resistant rickets</td>
<td>5C63.21</td>
</tr>
<tr>
<td>195</td>
<td>Disorders of calcium or phosphate excretion</td>
<td>GB90.48</td>
</tr>
<tr>
<td>196</td>
<td>Other specified defects in the complement system</td>
<td>4A00.1Y</td>
</tr>
<tr>
<td>197</td>
<td>Other specified monogenic autoinflammatory syndromes</td>
<td>4A60.Y</td>
</tr>
<tr>
<td>198</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</td>
<td>PL00</td>
</tr>
<tr>
<td>199</td>
<td>Other specified adult osteomalacia</td>
<td>FB83.2Y</td>
</tr>
<tr>
<td>200</td>
<td>Immune dysregulation syndromes presenting primarily with lymphoproliferation</td>
<td>4A01.22</td>
</tr>
<tr>
<td>201</td>
<td>Haemoglobin E disease</td>
<td>3A51.A</td>
</tr>
<tr>
<td>202</td>
<td>Vitamin E deficiency</td>
<td>5B58</td>
</tr>
<tr>
<td>203</td>
<td>Complete trisomy 18</td>
<td>LD40.2</td>
</tr>
<tr>
<td>204</td>
<td>Hereditary sensory and autonomic neuropathy type I</td>
<td>8C21.0</td>
</tr>
<tr>
<td>205</td>
<td>Other specified hazardous substance use</td>
<td>QE1Y</td>
</tr>
<tr>
<td>206</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>207</td>
<td>Other specified sickle cell disorders or other haemoglobinopathies</td>
<td>3A51.Y</td>
</tr>
<tr>
<td>208</td>
<td>Vaping related disorder</td>
<td>RA00.0</td>
</tr>
<tr>
<td>209</td>
<td>Chronic hepatitis E</td>
<td>1E51.3</td>
</tr>
<tr>
<td>210</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>211</td>
<td>Acute hepatitis E</td>
<td>1E50.4</td>
</tr>
<tr>
<td>212</td>
<td>Hyperimmunoglobulin E syndromes</td>
<td>4A01.34</td>
</tr>
<tr>
<td>213</td>
<td>Syndromes with lissencephaly as a major feature</td>
<td>LD20.1</td>
</tr>
<tr>
<td>214</td>
<td>Complex brachydactylies</td>
<td>LD26.1</td>
</tr>
<tr>
<td>215</td>
<td>Dementia due to other specified diseases classified elsewhere</td>
<td>6D85.Y</td>
</tr>
<tr>
<td>216</td>
<td>Acquired vitamin E deficiency anaemia</td>
<td>3A03.6</td>
</tr>
<tr>
<td>217</td>
<td>Peripheral neuropathy due to vitamin E deficiency</td>
<td>5B58/8D40.1</td>
</tr>
<tr>
<td>218</td>
<td>Urinary tract infection, site not specified, due to Escherichia coli</td>
<td>GC08.0</td>
</tr>
<tr>
<td>219</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
<td>5C50.B</td>
</tr>
<tr>
<td>220</td>
<td>Friedreich ataxia</td>
<td>8A03.10</td>
</tr>
<tr>
<td>221</td>
<td>Xeroderma pigmentosum</td>
<td>LD27.1</td>
</tr>
<tr>
<td>222</td>
<td>Beta thalassaemia</td>
<td>3A50.2</td>
</tr>
<tr>
<td>223</td>
<td>Other specified ectodermal dysplasia syndromes</td>
<td>LD27.0Y</td>
</tr>
<tr>
<td>224</td>
<td>Meningitis due to Escherichia coli</td>
<td>1D01.0Y&amp;XN6P4</td>
</tr>
<tr>
<td>225</td>
<td>Pneumonia due to Escherichia coli</td>
<td>CA40.01</td>
</tr>
<tr>
<td>226</td>
<td>Sepsis due to Escherichia coli infection without mention of septic shock</td>
<td>1C41&amp;XN6P4/1G40</td>
</tr>
<tr>
<td>227</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>228</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
<td>8C20.0</td>
</tr>
<tr>
<td>229</td>
<td>Escherichia coli peritonitis</td>
<td>DC50.1Y&amp;XN6P4</td>
</tr>
<tr>
<td>230</td>
<td>Spinocerebellar ataxia due to vitamin E deficiency</td>
<td>5B58/8A03.3Y</td>
</tr>
<tr>
<td>231</td>
<td>Acute or subacute fulminant hepatitis due to hepatitis E virus</td>
<td>DB91.0&amp;XN7TG</td>
</tr>
<tr>
<td>232</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>233</td>
<td>Pyruvate dehydrogenase complex deficiency</td>
<td>5C53.02</td>
</tr>
<tr>
<td>234</td>
<td>Exostoses with anetodermia and brachydactyly type E</td>
<td>LD24.21</td>
</tr>
<tr>
<td>235</td>
<td>Mixed hyperlipidaemia</td>
<td>5C80.2</td>
</tr>
<tr>
<td>236</td>
<td>Bacteraemia</td>
<td>MA15.0</td>
</tr>
<tr>
<td>237</td>
<td>Dystonia associated with heredodegenerative disorders</td>
<td>8A02.12</td>
</tr>
<tr>
<td>238</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>239</td>
<td>Extended spectrum beta-lactamase producing Escherichia coli</td>
<td>MG50.27</td>
</tr>
<tr>
<td>240</td>
<td>Laceration of liver, major</td>
<td>NB91.13</td>
</tr>
<tr>
<td>241</td>
<td>Other specified secondary hypertension</td>
<td>BA04.Y</td>
</tr>
<tr>
<td>242</td>
<td>Laceration of liver, moderate</td>
<td>NB91.12</td>
</tr>
<tr>
<td>243</td>
<td>Other specified congenital hypothyroidism</td>
<td>5A00.0Y</td>
</tr>
<tr>
<td>244</td>
<td>Laceration of liver, minor</td>
<td>NB91.11</td>
</tr>
<tr>
<td>245</td>
<td>Other B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities</td>
<td>2A70.Y</td>
</tr>
<tr>
<td>246</td>
<td>Hereditary persistence of fetal haemoglobin</td>
<td>3A50.4</td>
</tr>
<tr>
<td>247</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>248</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>249</td>
<td>Delta, delta-beta or gamma-delta-beta thalassaemia</td>
<td>3A50.3</td>
</tr>
<tr>
<td>250</td>
<td>Syndromes with lissencephaly as a major feature</td>
<td>LD20.1</td>
</tr>
<tr>
<td>251</td>
<td>Xeroderma pigmentosum</td>
<td>LD27.1</td>
</tr>
<tr>
<td>252</td>
<td>Syndromic ichthyosis</td>
<td>LD27.2</td>
</tr>
<tr>
<td>253</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>254</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
<td>8C20.0</td>
</tr>
<tr>
<td>255</td>
<td>Classical organic aciduria</td>
<td>5C50.E0</td>
</tr>
<tr>
<td>256</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>257</td>
<td>Other specified disorders of mitochondrial oxidative phosphorylation</td>
<td>5C53.2Y</td>
</tr>
<tr>
<td>258</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>259</td>
<td>Other specified effects of external causes</td>
<td>NF0Y</td>
</tr>
<tr>
<td>260</td>
<td>Glycogen storage disease</td>
<td>5C51.3</td>
</tr>
<tr>
<td>261</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>262</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>263</td>
<td>Hyperprolactinaemia</td>
<td>5A60.1</td>
</tr>
<tr>
<td>264</td>
<td>Neuroendocrine neoplasm of duodenum</td>
<td>2B80.01</td>
</tr>
<tr>
<td>265</td>
<td>Neoplasms of unknown behaviour of oral cavity or digestive organs, unspecified site</td>
<td>2F90.Z</td>
</tr>
<tr>
<td>266</td>
<td>Malignant G cell tumour of pancreas</td>
<td>2C10.1&amp;XH8DS0</td>
</tr>
<tr>
<td>267</td>
<td>Other specified syndromes with multiple structural anomalies, not of environmental origin</td>
<td>LD2F.1Y</td>
</tr>
<tr>
<td>268</td>
<td>Haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency</td>
<td>3A10.00</td>
</tr>
<tr>
<td>269</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
<td>5C50.B</td>
</tr>
<tr>
<td>270</td>
<td>Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells</td>
<td>4A01.04</td>
</tr>
<tr>
<td>271</td>
<td>Large newborn for gestational age</td>
<td>KA22.1</td>
</tr>
<tr>
<td>272</td>
<td>Xeroderma pigmentosum</td>
<td>LD27.1</td>
</tr>
<tr>
<td>273</td>
<td>Dystonia associated with heredodegenerative disorders</td>
<td>8A02.12</td>
</tr>
<tr>
<td>274</td>
<td>Neuroendocrine tumour, G2 of oesophagus</td>
<td>2B70.Y&amp;XH51K1</td>
</tr>
<tr>
<td>275</td>
<td>Other specified ectodermal dysplasia syndromes</td>
<td>LD27.0Y</td>
</tr>
<tr>
<td>276</td>
<td>Malignant neuroendocrine neoplasm of stomach</td>
<td>2B72.1</td>
</tr>
<tr>
<td>277</td>
<td>Penicillin resistant Streptococcus pneumoniae</td>
<td>MG51.10</td>
</tr>
<tr>
<td>278</td>
<td>Other specified malignant neoplasms of colon</td>
<td>2B90.Y</td>
</tr>
<tr>
<td>279</td>
<td>Neuroendocrine neoplasms of appendix</td>
<td>2B81.2</td>
</tr>
<tr>
<td>280</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>281</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
<td>8C20.0</td>
</tr>
<tr>
<td>282</td>
<td>Other specified pemphigoid</td>
<td>EB41.Y</td>
</tr>
<tr>
<td>283</td>
<td>Neuroendocrine neoplasms of small intestine, site unspecified</td>
<td>2B80.21</td>
</tr>
<tr>
<td>284</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>285</td>
<td>Neuroendocrine neoplasms of jejunum or ileum</td>
<td>2B80.11</td>
</tr>
<tr>
<td>286</td>
<td>Low birth weight of newborn, 2000-2499g</td>
<td>KA21.21</td>
</tr>
<tr>
<td>287</td>
<td>Low birth weight of newborn, 1500-1999g</td>
<td>KA21.20</td>
</tr>
<tr>
<td>288</td>
<td>Extremely low birth weight of newborn, 499g or less</td>
<td>KA21.00</td>
</tr>
<tr>
<td>289</td>
<td>Extremely low birth weight of newborn, 500-749g</td>
<td>KA21.01</td>
</tr>
<tr>
<td>290</td>
<td>Neuroendocrine tumour, G1 (carcinoid) of oesophagus</td>
<td>2B70.Y&amp;XH9LV8</td>
</tr>
<tr>
<td>291</td>
<td>Very low birth weight of newborn, 1000-1249g</td>
<td>KA21.10</td>
</tr>
<tr>
<td>292</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>293</td>
<td>Very low birth weight of newborn, 1250-1499g</td>
<td>KA21.11</td>
</tr>
<tr>
<td>294</td>
<td>Extremely low birth weight of newborn, 750-999g</td>
<td>KA21.02</td>
</tr>
<tr>
<td>295</td>
<td>Constitutional neutropaenia</td>
<td>4B00.00</td>
</tr>
<tr>
<td>296</td>
<td>Other specified hereditary thrombophilia</td>
<td>3B61.0Y</td>
</tr>
<tr>
<td>297</td>
<td>Other specified syndromes with skin or mucosal anomalies as a major feature</td>
<td>LD27.Y</td>
</tr>
<tr>
<td>298</td>
<td>Junctional epidermolysis bullosa</td>
<td>EC31</td>
</tr>
<tr>
<td>299</td>
<td>Noninflammatory inclusion body myopathy</td>
<td>4A41.21</td>
</tr>
<tr>
<td>300</td>
<td>Other specified disorders of urea cycle metabolism</td>
<td>5C50.AY</td>
</tr>
<tr>
<td>301</td>
<td>Mucopolysaccharidosis type 1</td>
<td>5C56.30</td>
</tr>
<tr>
<td>302</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>303</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>304</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>305</td>
<td>Dominant limb-girdle muscular dystrophy</td>
<td>8C70.40</td>
</tr>
<tr>
<td>306</td>
<td>Haemoglobin H disease (– α/– – included)</td>
<td>3A50.02</td>
</tr>
<tr>
<td>307</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
<td>NE60</td>
</tr>
<tr>
<td>308</td>
<td>Other specified defects in the complement system</td>
<td>4A00.1Y</td>
</tr>
<tr>
<td>309</td>
<td>Leukodystrophies, unspecified</td>
<td>8A44.Z</td>
</tr>
<tr>
<td>310</td>
<td>Meningitis due to Haemophilus influenzae</td>
<td>1D01.00</td>
</tr>
<tr>
<td>311</td>
<td>Pneumonia due to Haemophilus influenzae</td>
<td>CA40.02</td>
</tr>
<tr>
<td>312</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>313</td>
<td>Other specified sickle cell disorders or other haemoglobinopathies</td>
<td>3A51.Y</td>
</tr>
<tr>
<td>314</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
<td>8C20.0</td>
</tr>
<tr>
<td>315</td>
<td>Unintentional exposure to or harmful effects of other H1-receptor antagonists</td>
<td>PB28&amp;XM4J58</td>
</tr>
<tr>
<td>316</td>
<td>Intentional self-harm by exposure to or harmful effects of other H1-receptor antagonists</td>
<td>PC98&amp;XE13E&amp;XM4J58</td>
</tr>
<tr>
<td>317</td>
<td>Influenza due to infection with Influenza A/H5N1 virus</td>
<td>1E31&amp;XN4TT</td>
</tr>
<tr>
<td>318</td>
<td>Influenza due to infection with Influenza A/H1N1 virus</td>
<td>1E31&amp;XN297</td>
</tr>
<tr>
<td>319</td>
<td>Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances</td>
<td>PH48</td>
</tr>
<tr>
<td>320</td>
<td>Other specified hereditary haemolytic anaemia</td>
<td>3A10.Y</td>
</tr>
<tr>
<td>321</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</td>
<td>PL00</td>
</tr>
<tr>
<td>322</td>
<td>Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
<td>PB28</td>
</tr>
<tr>
<td>323</td>
<td>Other specified acquired haemolytic anaemia, non-immune</td>
<td>3A21.Y</td>
</tr>
<tr>
<td>324</td>
<td>Influenza due to infection with Influenza A/H7N9 virus</td>
<td>1E31&amp;XN35G</td>
</tr>
<tr>
<td>325</td>
<td>Assault by exposure to or harmful effects of other H1-receptor antagonists</td>
<td>PE88&amp;XM4J58</td>
</tr>
<tr>
<td>326</td>
<td>Bacteraemia</td>
<td>MA15.0</td>
</tr>
<tr>
<td>327</td>
<td>Intentional self-harm by exposure to other or unspecified drug, medicament or biological substance</td>
<td>PC98</td>
</tr>
<tr>
<td>328</td>
<td>Assault by exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
<td>PE88</td>
</tr>
<tr>
<td>329</td>
<td>Bacterial pneumonia, unspecified</td>
<td>CA40.0Z</td>
</tr>
<tr>
<td>330</td>
<td>Harmful effects of or exposure to noxious substances chiefly nonmedicinal as to source, benzene</td>
<td>NE61&amp;XM0QY7</td>
</tr>
<tr>
<td>331</td>
<td>Other specified nonstructural developmental anomalies of small intestine</td>
<td>DA90.Y</td>
</tr>
<tr>
<td>332</td>
<td>Mucolipidosis</td>
<td>5C56.20</td>
</tr>
<tr>
<td>333</td>
<td>Dystrophic epidermolysis bullosa</td>
<td>EC32</td>
</tr>
<tr>
<td>334</td>
<td>Low grade squamous intraepithelial lesion of vagina</td>
<td>GA14.6</td>
</tr>
<tr>
<td>335</td>
<td>Low grade squamous intraepithelial lesion of cervix uteri</td>
<td>GA15.7</td>
</tr>
<tr>
<td>336</td>
<td>Low grade squamous intraepithelial lesion of vulva</td>
<td>GA13.1</td>
</tr>
<tr>
<td>337</td>
<td>Hereditary angioedema</td>
<td>4A00.14</td>
</tr>
<tr>
<td>338</td>
<td>Respiratory failure, unspecified, Type I</td>
<td>CB41.20</td>
</tr>
<tr>
<td>339</td>
<td>Complex regional pain syndrome</td>
<td>MG30.04</td>
</tr>
<tr>
<td>340</td>
<td>Total anomalous pulmonary venous connection</td>
<td>LA86.20</td>
</tr>
<tr>
<td>341</td>
<td>Disorders of cobalamin metabolism or transport</td>
<td>5C63.0</td>
</tr>
<tr>
<td>342</td>
<td>Hereditary deficiency of factor I</td>
<td>3B14.0</td>
</tr>
<tr>
<td>343</td>
<td>Bone dysplasias with multiple joint dislocations</td>
<td>LD24.E</td>
</tr>
<tr>
<td>344</td>
<td>Other specified functional neutrophil defects</td>
<td>4A00.0Y</td>
</tr>
<tr>
<td>345</td>
<td>Acute respiratory failure, Type I</td>
<td>CB41.00</td>
</tr>
<tr>
<td>346</td>
<td>Bipolar type I disorder, unspecified</td>
<td>6A60.Z</td>
</tr>
<tr>
<td>347</td>
<td>Chronic respiratory failure, Type I</td>
<td>CB41.10</td>
</tr>
<tr>
<td>348</td>
<td>Arnold-Chiari malformation type I</td>
<td>LA07.4</td>
</tr>
<tr>
<td>349</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>350</td>
<td>Thanatophoric dysplasia</td>
<td>LD24.02</td>
</tr>
<tr>
<td>351</td>
<td>Infantile spinal muscular atrophy, Type I</td>
<td>8B61.0</td>
</tr>
<tr>
<td>352</td>
<td>Pressure ulceration grade 1</td>
<td>EH90.0</td>
</tr>
<tr>
<td>353</td>
<td>Laryngotracheooesophageal cleft</td>
<td>LA72</td>
</tr>
<tr>
<td>354</td>
<td>Other specified bipolar type I disorder</td>
<td>6A60.Y</td>
</tr>
<tr>
<td>355</td>
<td>Congenital portosystemic shunt</td>
<td>LA90.21</td>
</tr>
<tr>
<td>356</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>357</td>
<td>Atresia of small intestine</td>
<td>LB15.1</td>
</tr>
<tr>
<td>358</td>
<td>Cortical dysplasia</td>
<td>LA05.51</td>
</tr>
<tr>
<td>359</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
<td>5C50.B</td>
</tr>
<tr>
<td>360</td>
<td>Hypocalcaemic vitamin D dependent rickets</td>
<td>5C63.20</td>
</tr>
<tr>
<td>361</td>
<td>Other specified types of Ehlers-Danlos syndrome</td>
<td>LD28.1Y</td>
</tr>
<tr>
<td>362</td>
<td>Female Genital Mutilation Type 1, unspecified</td>
<td>GC51.0Z</td>
</tr>
<tr>
<td>363</td>
<td>Other specified inflammatory or other diseases of prostate</td>
<td>GA91.Y</td>
</tr>
<tr>
<td>364</td>
<td>Langerhans cell histiocytosis involving the skin</td>
<td>2B31.20</td>
</tr>
<tr>
<td>365</td>
<td>Classical phenylketonuria</td>
<td>5C50.00</td>
</tr>
<tr>
<td>366</td>
<td>Congenital sucrase-isomaltase deficiency</td>
<td>5C61.2</td>
</tr>
<tr>
<td>367</td>
<td>Single umbilical cord artery</td>
<td>LB03.1</td>
</tr>
<tr>
<td>368</td>
<td>Obesity in adults with BMI 30.00-34.99 kg/m²</td>
<td>5B81.01&amp;XS3Y</td>
</tr>
<tr>
<td>369</td>
<td>First degree haemorrhoids</td>
<td>DB60.0</td>
</tr>
<tr>
<td>370</td>
<td>Thoracic aortic dissection, ascending aorta dissection and propagation beyond arch, without mention of perforation or rupture</td>
<td>BD50.0Z</td>
</tr>
<tr>
<td>371</td>
<td>Disorders of carnitine transport or the carnitine cycle</td>
<td>5C52.00</td>
</tr>
<tr>
<td>372</td>
<td>Other specified structural developmental anomalies of umbilical cord</td>
<td>LB03.Y</td>
</tr>
<tr>
<td>373</td>
<td>Other specified defects in the complement system</td>
<td>4A00.1Y</td>
</tr>
<tr>
<td>374</td>
<td>Primary lymphoedema</td>
<td>BD93.0</td>
</tr>
<tr>
<td>375</td>
<td>Fracture of odontoid process</td>
<td>NA22.12</td>
</tr>
<tr>
<td>376</td>
<td>Biventricular failure NYHA Class I</td>
<td>BD14&amp;XS3A</td>
</tr>
<tr>
<td>377</td>
<td>Congenital dyserythropoietic anaemia</td>
<td>3A73</td>
</tr>
<tr>
<td>378</td>
<td>Other specified mitochondrial myopathies</td>
<td>8C73.Y</td>
</tr>
<tr>
<td>379</td>
<td>Left ventricular failure NYHA Class I</td>
<td>BD11.Z&amp;XS3A</td>
</tr>
<tr>
<td>380</td>
<td>Cryoglobulinaemia</td>
<td>4B22</td>
</tr>
<tr>
<td>381</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>382</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>383</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>384</td>
<td>J-shaped sella turcica</td>
<td>LB70.2</td>
</tr>
<tr>
<td>385</td>
<td>Early repolarisation syndrome</td>
<td>BC65.3</td>
</tr>
<tr>
<td>386</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>387</td>
<td>Charcot-Marie-Tooth disease 1 demyelinating</td>
<td>8C20.0</td>
</tr>
<tr>
<td>388</td>
<td>Vitamin K deficiency</td>
<td>5B59</td>
</tr>
<tr>
<td>389</td>
<td>Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells</td>
<td>4A01.04</td>
</tr>
<tr>
<td>390</td>
<td>Hypokalaemia</td>
<td>5C77</td>
</tr>
<tr>
<td>391</td>
<td>Hyperkalaemia</td>
<td>5C76</td>
</tr>
<tr>
<td>392</td>
<td>Other specified lysosomal diseases</td>
<td>5C56.Y</td>
</tr>
<tr>
<td>393</td>
<td>Follow-up care involving removal of fracture plate or other internal fixation device</td>
<td>QB84</td>
</tr>
<tr>
<td>394</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>395</td>
<td>Neonatal vitamin K deficiency, unspecified</td>
<td>KA8F.Z</td>
</tr>
<tr>
<td>396</td>
<td>Epidermolysis bullosa simplex</td>
<td>EC30</td>
</tr>
<tr>
<td>397</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>398</td>
<td>Other specified haemorrhagic diseases due to acquired coagulation factor defects</td>
<td>3B2Y</td>
</tr>
<tr>
<td>399</td>
<td>Other specified neonatal vitamin K deficiency</td>
<td>KA8F.Y</td>
</tr>
<tr>
<td>400</td>
<td>Embryofetopathy due to oral anticoagulant therapy</td>
<td>LD2F.02</td>
</tr>
<tr>
<td>401</td>
<td>Haemorrhagic disorder due to other specified circulating anticoagulants or coagulation factors</td>
<td>3B21.Y</td>
</tr>
<tr>
<td>402</td>
<td>Diffuse bleeding diathesis due to vitamin K deficient haemorrhagic disease of fetus or newborn</td>
<td>KA8F.0</td>
</tr>
<tr>
<td>403</td>
<td>Combined deficiency of vitamin K-dependent clotting factors</td>
<td>3B14.2</td>
</tr>
<tr>
<td>404</td>
<td>Other inherited coagulation factor deficiency with bleeding tendency, unspecified</td>
<td>3B14.Z</td>
</tr>
<tr>
<td>405</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
<td>NE60</td>
</tr>
<tr>
<td>406</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>407</td>
<td>Unintentional exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
<td>PB28</td>
</tr>
<tr>
<td>408</td>
<td>Intentional self-harm by exposure to or harmful effects of anticoagulant antagonists, vitamin K or other coagulants</td>
<td>PC98&amp;XE13E</td>
</tr>
<tr>
<td>409</td>
<td>Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances</td>
<td>PH48</td>
</tr>
<tr>
<td>410</td>
<td>Assault by exposure to or harmful effects of other or unspecified drug, medicament or biological substance</td>
<td>PE88</td>
</tr>
<tr>
<td>411</td>
<td>Drugs, medicaments or biological substances associated with injury or harm in therapeutic use</td>
<td>PL00</td>
</tr>
<tr>
<td>412</td>
<td>Other specified conditions with disorders of intellectual development as a relevant clinical feature</td>
<td>LD90.Y</td>
</tr>
<tr>
<td>413</td>
<td>Disorders of the pentose phosphate pathway</td>
<td>5C51.0</td>
</tr>
<tr>
<td>414</td>
<td>Mucopolysaccharidosis type 1</td>
<td>5C56.30</td>
</tr>
<tr>
<td>415</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
<td>NE60</td>
</tr>
<tr>
<td>416</td>
<td>Abnormal ventricular relationships</td>
<td>LA81</td>
</tr>
<tr>
<td>417</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>418</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>419</td>
<td>Cerebral organic aciduria</td>
<td>5C50.E1</td>
</tr>
<tr>
<td>420</td>
<td>Oligosaccharidosis</td>
<td>5C56.21</td>
</tr>
<tr>
<td>421</td>
<td>Other specified structural developmental anomaly of heart or great vessels</td>
<td>LA8Y</td>
</tr>
<tr>
<td>422</td>
<td>Fracture of second lumbar vertebra</td>
<td>NB52.0&amp;XA2GH9</td>
</tr>
<tr>
<td>423</td>
<td>Fracture of first lumbar vertebra</td>
<td>NB52.0&amp;XA3291</td>
</tr>
<tr>
<td>424</td>
<td>Brown-Sequard syndrome at L2 level</td>
<td>NB62.4&amp;XA8X63</td>
</tr>
<tr>
<td>425</td>
<td>Brown-Sequard syndrome at L1 level</td>
<td>NB62.4&amp;XA6TL5</td>
</tr>
<tr>
<td>426</td>
<td>Fracture of third lumbar vertebra</td>
<td>NB52.0&amp;XA3N97</td>
</tr>
<tr>
<td>427</td>
<td>Brown-Sequard syndrome at L3 level</td>
<td>NB62.4&amp;XA57M0</td>
</tr>
<tr>
<td>428</td>
<td>Fracture of fourth lumbar vertebra</td>
<td>NB52.0&amp;XA9A53</td>
</tr>
<tr>
<td>429</td>
<td>Fracture of fifth lumbar vertebra</td>
<td>NB52.0&amp;XA9641</td>
</tr>
<tr>
<td>430</td>
<td>Unintentional exposure to or harmful effects of L-DOPA</td>
<td>PB27&amp;XM7SN1</td>
</tr>
<tr>
<td>431</td>
<td>Brown-Sequard syndrome at L4 level</td>
<td>NB62.4&amp;XA1ZV5</td>
</tr>
<tr>
<td>432</td>
<td>Brown-Sequard syndrome at L5 level</td>
<td>NB62.4&amp;XA86M5</td>
</tr>
<tr>
<td>433</td>
<td>Intentional self-harm by exposure to or harmful effects of L-DOPA</td>
<td>PC97&amp;XM7SN1</td>
</tr>
<tr>
<td>434</td>
<td>Harmful effects of or exposure to L-DOPA, undetermined intent</td>
<td>PH47.Z&amp;XM7SN1</td>
</tr>
<tr>
<td>435</td>
<td>Central cord syndrome of lumbar spinal cord at L2 level</td>
<td>NB62.1&amp;XA8X63</td>
</tr>
<tr>
<td>436</td>
<td>Dislocation of lumbar vertebra</td>
<td>NB53.1</td>
</tr>
<tr>
<td>437</td>
<td>Anterior cord syndrome of lumbar spinal cord at L2 level</td>
<td>NB62.2&amp;XA8X63</td>
</tr>
<tr>
<td>438</td>
<td>Central cord syndrome of lumbar spinal cord at L1 level</td>
<td>NB62.1&amp;XA6TL5</td>
</tr>
<tr>
<td>439</td>
<td>Posterior cord syndrome of lumbar spinal cord at L2 level</td>
<td>NB62.3&amp;XA8X63</td>
</tr>
<tr>
<td>440</td>
<td>Anterior cord syndrome of lumbar spinal cord at L1 level</td>
<td>NB62.2&amp;XA6TL5</td>
</tr>
<tr>
<td>441</td>
<td>Posterior cord syndrome of lumbar spinal cord at L1 level</td>
<td>NB62.3&amp;XA6TL5</td>
</tr>
<tr>
<td>442</td>
<td>Central cord syndrome of lumbar spinal cord at L3 level</td>
<td>NB62.1&amp;XA57M0</td>
</tr>
<tr>
<td>443</td>
<td>Anterior cord syndrome of lumbar spinal cord at L3 level</td>
<td>NB62.2&amp;XA57M0</td>
</tr>
<tr>
<td>444</td>
<td>Posterior cord syndrome of lumbar spinal cord at L3 level</td>
<td>NB62.3&amp;XA57M0</td>
</tr>
<tr>
<td>445</td>
<td>Central cord syndrome of lumbar spinal cord at L4 level</td>
<td>NB62.1&amp;XA1ZV5</td>
</tr>
<tr>
<td>446</td>
<td>Central cord syndrome of lumbar spinal cord at L5 level</td>
<td>NB62.1&amp;XA86M5</td>
</tr>
<tr>
<td>447</td>
<td>Anterior cord syndrome of lumbar spinal cord at L4 level</td>
<td>NB62.2&amp;XA1ZV5</td>
</tr>
<tr>
<td>448</td>
<td>Anterior cord syndrome of lumbar spinal cord at L5 level</td>
<td>NB62.2&amp;XA86M5</td>
</tr>
<tr>
<td>449</td>
<td>Complete lesion of lumbar spinal cord at L2 level</td>
<td>NB62.0&amp;XA8X63</td>
</tr>
<tr>
<td>450</td>
<td>Posterior cord syndrome of lumbar spinal cord at L4 level</td>
<td>NB62.3&amp;XA1ZV5</td>
</tr>
<tr>
<td>451</td>
<td>Posterior cord syndrome of lumbar spinal cord at L5 level</td>
<td>NB62.3&amp;XA86M5</td>
</tr>
<tr>
<td>452</td>
<td>Complete lesion of lumbar spinal cord at L1 level</td>
<td>NB62.0&amp;XA6TL5</td>
</tr>
<tr>
<td>453</td>
<td>Disorders of catecholamine synthesis</td>
<td>5C59.00</td>
</tr>
<tr>
<td>454</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>455</td>
<td>Other incomplete cord syndrome of lumbar spinal cord at L2 level</td>
<td>NB62.5&amp;XA8X63</td>
</tr>
<tr>
<td>456</td>
<td>Complete lesion of lumbar spinal cord at L3 level</td>
<td>NB62.0&amp;XA57M0</td>
</tr>
<tr>
<td>457</td>
<td>Other incomplete cord syndrome of lumbar spinal cord at L1 level</td>
<td>NB62.5&amp;XA6TL5</td>
</tr>
<tr>
<td>458</td>
<td>Complete lesion of lumbar spinal cord at L4 level</td>
<td>NB62.0&amp;XA1ZV5</td>
</tr>
<tr>
<td>459</td>
<td>Complete lesion of lumbar spinal cord at L5 level</td>
<td>NB62.0&amp;XA86M5</td>
</tr>
<tr>
<td>460</td>
<td>Other incomplete cord syndrome of lumbar spinal cord at L3 level</td>
<td>NB62.5&amp;XA57M0</td>
</tr>
<tr>
<td>461</td>
<td>Other specified combined immunodeficiencies</td>
<td>4A01.1Y</td>
</tr>
<tr>
<td>462</td>
<td>Other specified white matter disorders due to vascular abnormality or ischemia</td>
<td>8A45.2Y</td>
</tr>
<tr>
<td>463</td>
<td>Slender bone dysplasias</td>
<td>LD24.D</td>
</tr>
<tr>
<td>464</td>
<td>Hereditary methaemoglobinaemia</td>
<td>3A92</td>
</tr>
<tr>
<td>465</td>
<td>Irritable bowel syndrome, mixed type</td>
<td>DD91.02</td>
</tr>
<tr>
<td>466</td>
<td>Female Genital Mutilation, unspecified</td>
<td>GC51.Z</td>
</tr>
<tr>
<td>467</td>
<td>Multi organ failure</td>
<td>MG4A</td>
</tr>
<tr>
<td>468</td>
<td>Other specified oromandibular-limb anomaly syndrome</td>
<td>LD25.0Y</td>
</tr>
<tr>
<td>469</td>
<td>Acute monoblastic or monocytic leukaemia</td>
<td>2A60.34</td>
</tr>
<tr>
<td>470</td>
<td>Disorders of mitochondrial fatty acid oxidation</td>
<td>5C52.01</td>
</tr>
<tr>
<td>471</td>
<td>Acute megakaryoblastic leukaemia</td>
<td>2A60.36</td>
</tr>
<tr>
<td>472</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>473</td>
<td>Extreme prematurity of newborn, unspecified</td>
<td>KA21.3Z</td>
</tr>
<tr>
<td>474</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>475</td>
<td>Other specified congenital disorders of glycosylation and protein modification</td>
<td>5C54.Y</td>
</tr>
<tr>
<td>476</td>
<td>Cutaneous Mycobacterium fortuitum infection</td>
<td>1B21.2Y&amp;XN8ZX</td>
</tr>
<tr>
<td>477</td>
<td>Von Willebrand disease</td>
<td>3B12</td>
</tr>
<tr>
<td>478</td>
<td>Immunodeficiencies with isotype or light chain deficiencies with normal number of B cells</td>
<td>4A01.04</td>
</tr>
<tr>
<td>479</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>480</td>
<td>Dialysis-associated amyloidosis</td>
<td>5D00.3</td>
</tr>
<tr>
<td>481</td>
<td>Hereditary ATTR amyloidosis</td>
<td>5D00.20</td>
</tr>
<tr>
<td>482</td>
<td>Chronic kidney disease, stage 5</td>
<td>GB61.5</td>
</tr>
<tr>
<td>483</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>484</td>
<td>Chronic kidney disease, stage 4</td>
<td>GB61.4</td>
</tr>
<tr>
<td>485</td>
<td>Chronic kidney disease, stage 3b</td>
<td>GB61.3</td>
</tr>
<tr>
<td>486</td>
<td>Chronic kidney disease, stage 1</td>
<td>GB61.0</td>
</tr>
<tr>
<td>487</td>
<td>Chronic kidney disease, stage 2</td>
<td>GB61.1</td>
</tr>
<tr>
<td>488</td>
<td>Chronic kidney disease, stage 3a</td>
<td>GB61.2</td>
</tr>
<tr>
<td>489</td>
<td>Obesity, not elsewhere classified, body mass index &gt;= 40 kg/m²</td>
<td>5B81.Y&amp;XS6N</td>
</tr>
<tr>
<td>490</td>
<td>Obesity in adults with BMI greater than or equal to 40.00 kg/m²</td>
<td>5B81.01&amp;XS2B</td>
</tr>
<tr>
<td>491</td>
<td>Albuminuria, Grade A3</td>
<td>GB42.1</td>
</tr>
<tr>
<td>492</td>
<td>Obesity in adults with BMI 30.00-34.99 kg/m²</td>
<td>5B81.01&amp;XS3Y</td>
</tr>
<tr>
<td>493</td>
<td>Obesity in adults with BMI 35.00-39.99 kg/m²</td>
<td>5B81.01&amp;XS6N</td>
</tr>
<tr>
<td>494</td>
<td>Albuminuria, Grade A2</td>
<td>GB42.0</td>
</tr>
<tr>
<td>495</td>
<td>Drug-induced obesity with BMI 30.00-34.99 kg/m²</td>
<td>5B81.1&amp;XS3Y</td>
</tr>
<tr>
<td>496</td>
<td>Obesity, not elsewhere classified, body mass index &gt;= 35 kg/m² to m²</td>
<td>5B81.Y&amp;XS2B</td>
</tr>
<tr>
<td>497</td>
<td>Drug-induced obesity with BMI 35.00-39.99 kg/m²</td>
<td>5B81.1&amp;XS6N</td>
</tr>
<tr>
<td>498</td>
<td>Drug-induced obesity with BMI greater than or equal to 40.00 kg/m²</td>
<td>5B81.1&amp;XS2B</td>
</tr>
<tr>
<td>499</td>
<td>Obesity, not elsewhere classified, body mass index &gt;= 30 kg/m2 to m2</td>
<td>5B81.Y&amp;XS3Y</td>
</tr>
<tr>
<td>500</td>
<td>Obesity hypoventilation syndrome</td>
<td>7A42.0</td>
</tr>
<tr>
<td>501</td>
<td>Other specified elevated blood glucose level</td>
<td>MA18.0Y</td>
</tr>
<tr>
<td>502</td>
<td>Paraneoplastic or autoimmune disorders of the peripheral or autonomic nervous system</td>
<td>8E4A.1</td>
</tr>
<tr>
<td>503</td>
<td>Other specified syndromic genetic deafness</td>
<td>LD2H.Y</td>
</tr>
<tr>
<td>504</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>505</td>
<td>Compressive optic neuropathy</td>
<td>9C40.5</td>
</tr>
<tr>
<td>506</td>
<td>Other specified mucopolysaccharidosis</td>
<td>5C56.3Y</td>
</tr>
<tr>
<td>507</td>
<td>Injury of abducent nerve</td>
<td>NA04.5</td>
</tr>
<tr>
<td>508</td>
<td>Oligosaccharidosis</td>
<td>5C56.21</td>
</tr>
<tr>
<td>509</td>
<td>Injury of axillary nerve</td>
<td>NC14.3</td>
</tr>
<tr>
<td>510</td>
<td>Injury of trigeminal nerve</td>
<td>NA04.4</td>
</tr>
<tr>
<td>511</td>
<td>Injury of facial nerve</td>
<td>NA04.6</td>
</tr>
<tr>
<td>512</td>
<td>Injury of oculomotor nerve</td>
<td>NA04.2</td>
</tr>
<tr>
<td>513</td>
<td>Injury of trochlear nerve</td>
<td>NA04.3</td>
</tr>
<tr>
<td>514</td>
<td>Injury of accessory nerve</td>
<td>NA04.A</td>
</tr>
<tr>
<td>515</td>
<td>Injury of musculocutaneous nerve</td>
<td>NC14.4</td>
</tr>
<tr>
<td>516</td>
<td>Citrullinaemia</td>
<td>5C50.A3</td>
</tr>
<tr>
<td>517</td>
<td>Paralysis of vocal cords or larynx</td>
<td>CA0H.0</td>
</tr>
<tr>
<td>518</td>
<td>Other specified disorder of the optic nerve</td>
<td>9C40.Y</td>
</tr>
<tr>
<td>519</td>
<td>Disorders of methionine cycle or sulphur amino acid metabolism</td>
<td>5C50.B</td>
</tr>
<tr>
<td>520</td>
<td>Von Willebrand disease</td>
<td>3B12</td>
</tr>
<tr>
<td>521</td>
<td>Injury of lateral plantar nerve</td>
<td>ND15.0</td>
</tr>
<tr>
<td>522</td>
<td>Mucopolysaccharidosis type 6</td>
<td>5C56.33</td>
</tr>
<tr>
<td>523</td>
<td>Injury of medial plantar nerve</td>
<td>ND15.1</td>
</tr>
<tr>
<td>524</td>
<td>Injury of digital nerve of thumb</td>
<td>NC55.Y&amp;XA37M8</td>
</tr>
<tr>
<td>525</td>
<td>Disorders of protein O-glycosylation</td>
<td>5C54.1</td>
</tr>
<tr>
<td>526</td>
<td>Multiple osteochondromas</td>
<td>LD24.20</td>
</tr>
<tr>
<td>527</td>
<td>Mucolipidosis</td>
<td>5C56.20</td>
</tr>
<tr>
<td>528</td>
<td>Paraneoplastic or autoimmune disorders of the central nervous system, brain or spinal cord</td>
<td>8E4A.0</td>
</tr>
<tr>
<td>529</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>530</td>
<td>Influenza due to infection with Influenza A/H5N1 virus</td>
<td>1E31&amp;XN4TT</td>
</tr>
<tr>
<td>531</td>
<td>Other specified disorders of urea cycle metabolism</td>
<td>5C50.AY</td>
</tr>
<tr>
<td>532</td>
<td>Other specified disorders of glycine metabolism</td>
<td>5C50.7Y</td>
</tr>
<tr>
<td>533</td>
<td>Influenza due to infection with Influenza A/H1N1 virus</td>
<td>1E31&amp;XN297</td>
</tr>
<tr>
<td>534</td>
<td>Immunodeficiencies with severe reduction in serum IgG or IgA with normal or elevated IgM and normal numbers of B-cells</td>
<td>4A01.05</td>
</tr>
<tr>
<td>535</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>536</td>
<td>Gangliosidosis</td>
<td>5C56.00</td>
</tr>
<tr>
<td>537</td>
<td>Influenza due to infection with Influenza A/H7N9 virus</td>
<td>1E31&amp;XN35G</td>
</tr>
<tr>
<td>538</td>
<td>Autoimmune disorders involving the autonomic nervous system</td>
<td>8D82</td>
</tr>
<tr>
<td>539</td>
<td>Dystrophic epidermolysis bullosa</td>
<td>EC32</td>
</tr>
<tr>
<td>540</td>
<td>Haemoglobin O disease</td>
<td>3A51.9</td>
</tr>
<tr>
<td>541</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>542</td>
<td>Actinic elastosis</td>
<td>EJ20.0</td>
</tr>
<tr>
<td>543</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>544</td>
<td>Disorders of protein O-glycosylation</td>
<td>5C54.1</td>
</tr>
<tr>
<td>545</td>
<td>O'nyong-nyong fever</td>
<td>1D42</td>
</tr>
<tr>
<td>546</td>
<td>Compound heterozygous sickling disorders without crisis</td>
<td>3A51.3</td>
</tr>
<tr>
<td>547</td>
<td>Cholera due to Vibrio cholerae O139</td>
<td>1A00&amp;XN8KD</td>
</tr>
<tr>
<td>548</td>
<td>Cholera due to Vibrio cholerae O1, biovar cholerae</td>
<td>1A00&amp;XN8P1</td>
</tr>
<tr>
<td>549</td>
<td>Charcot-Marie-Tooth disease 2 axonal</td>
<td>8C20.1</td>
</tr>
<tr>
<td>550</td>
<td>Cholera due to Vibrio cholerae O1, biovar eltor</td>
<td>1A00&amp;XN62R</td>
</tr>
<tr>
<td>551</td>
<td>Cholera</td>
<td>1A00</td>
</tr>
<tr>
<td>552</td>
<td>Other specified undernutrition</td>
<td>5B7Y</td>
</tr>
<tr>
<td>553</td>
<td>Multiple system atrophy, Parkinsonism</td>
<td>8D87.01</td>
</tr>
<tr>
<td>554</td>
<td>Preterm premature rupture of membranes</td>
<td>JA89.3</td>
</tr>
<tr>
<td>555</td>
<td>Deletions of the short arm of chromosome 5</td>
<td>LD44.51</td>
</tr>
<tr>
<td>556</td>
<td>Duplications of the short arm of chromosome 4</td>
<td>LD41.31</td>
</tr>
<tr>
<td>557</td>
<td>Duplications of the short arm of chromosome 5</td>
<td>LD41.41</td>
</tr>
<tr>
<td>558</td>
<td>Duplications of the short arm of chromosome 12</td>
<td>LD41.B1</td>
</tr>
<tr>
<td>559</td>
<td>Duplications of the short arm of chromosome 10</td>
<td>LD41.91</td>
</tr>
<tr>
<td>560</td>
<td>Duplications of the short arm of chromosome 7</td>
<td>LD41.61</td>
</tr>
<tr>
<td>561</td>
<td>Duplications of the short arm of chromosome 8</td>
<td>LD41.71</td>
</tr>
<tr>
<td>562</td>
<td>Duplications of the short arm of chromosome 9</td>
<td>LD41.81</td>
</tr>
<tr>
<td>563</td>
<td>Duplications of the short arm of chromosome 20</td>
<td>LD41.K1</td>
</tr>
<tr>
<td>564</td>
<td>Duplications of the short arm of chromosome 18</td>
<td>LD41.H1</td>
</tr>
<tr>
<td>565</td>
<td>Duplications of the short arm of chromosome 17</td>
<td>LD41.G1</td>
</tr>
<tr>
<td>566</td>
<td>Deletions of the short arm of chromosome 9</td>
<td>LD44.91</td>
</tr>
<tr>
<td>567</td>
<td>Deletions of the short arm of chromosome 18</td>
<td>LD44.J1</td>
</tr>
<tr>
<td>568</td>
<td>Other specified chromosomal anomalies, excluding gene mutations</td>
<td>LD7Y</td>
</tr>
<tr>
<td>569</td>
<td>Deletions of the short arm of chromosome 2</td>
<td>LD44.21</td>
</tr>
<tr>
<td>570</td>
<td>Other specified diseases of the skin</td>
<td>EM0Y</td>
</tr>
<tr>
<td>571</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>572</td>
<td>Deletions of the short arm of chromosome 4</td>
<td>LD44.41</td>
</tr>
<tr>
<td>573</td>
<td>Deletions of the short arm of chromosome 1</td>
<td>LD44.11</td>
</tr>
<tr>
<td>574</td>
<td>Duplications of the short arm of chromosome 6</td>
<td>LD41.51</td>
</tr>
<tr>
<td>575</td>
<td>Deletions of the short arm of chromosome 6</td>
<td>LD44.61</td>
</tr>
<tr>
<td>576</td>
<td>Deletions of the short arm of chromosome 11</td>
<td>LD44.B1</td>
</tr>
<tr>
<td>577</td>
<td>Duplications of the short arm of chromosome 2</td>
<td>LD41.11</td>
</tr>
<tr>
<td>578</td>
<td>Duplications of the short arm of chromosome 1</td>
<td>LD41.01</td>
</tr>
<tr>
<td>579</td>
<td>Other specified malformative disorders of sex development</td>
<td>LD2A.Y</td>
</tr>
<tr>
<td>580</td>
<td>Deletions of chromosome 5, unspecified</td>
<td>LD44.5Z</td>
</tr>
<tr>
<td>581</td>
<td>Duplications of the short arm of chromosome 3</td>
<td>LD41.21</td>
</tr>
<tr>
<td>582</td>
<td>Duplications of chromosome 11</td>
<td>LD41.A</td>
</tr>
<tr>
<td>583</td>
<td>Deletions of the short arm of chromosome 10</td>
<td>LD44.A1</td>
</tr>
<tr>
<td>584</td>
<td>Deletions of the short arm of chromosome 7</td>
<td>LD44.71</td>
</tr>
<tr>
<td>585</td>
<td>Deletions of the short arm of chromosome 20</td>
<td>LD44.L1</td>
</tr>
<tr>
<td>586</td>
<td>Deletions of the short arm of chromosome 8</td>
<td>LD44.81</td>
</tr>
<tr>
<td>587</td>
<td>Deletions of the short arm of chromosome 16</td>
<td>LD44.G1</td>
</tr>
<tr>
<td>588</td>
<td>Deletions of the short arm of chromosome 17</td>
<td>LD44.H1</td>
</tr>
<tr>
<td>589</td>
<td>Duplications of the short arm of chromosome 16</td>
<td>LD41.F1</td>
</tr>
<tr>
<td>590</td>
<td>Deletions of the short arm of chromosome 19</td>
<td>LD44.K1</td>
</tr>
<tr>
<td>591</td>
<td>Syndromes with lissencephaly as a major feature</td>
<td>LD20.1</td>
</tr>
<tr>
<td>592</td>
<td>Duplications with other complex rearrangements</td>
<td>LD41.P</td>
</tr>
<tr>
<td>593</td>
<td>Deletions of the short arm of chromosome 3</td>
<td>LD44.31</td>
</tr>
<tr>
<td>594</td>
<td>Constitutional neutropaenia</td>
<td>4B00.00</td>
</tr>
<tr>
<td>595</td>
<td>Structural anomalies of chromosome X, excluding Turner syndrome</td>
<td>LD51</td>
</tr>
<tr>
<td>596</td>
<td>Alpha thalassaemia related syndromes</td>
<td>3A50.1</td>
</tr>
<tr>
<td>597</td>
<td>Genetic susceptibility to particular pathogens</td>
<td>4A00.2</td>
</tr>
<tr>
<td>598</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>599</td>
<td>Other specified pemphigoid</td>
<td>EB41.Y</td>
</tr>
<tr>
<td>600</td>
<td>Other specified qualitative platelet defects</td>
<td>3B62.Y</td>
</tr>
<tr>
<td>601</td>
<td>Familial Parkinson disease</td>
<td>8A00.01</td>
</tr>
<tr>
<td>602</td>
<td>Myelodysplastic syndrome with isolated del(5q)</td>
<td>2A36</td>
</tr>
<tr>
<td>603</td>
<td>Deletions of chromosome 21</td>
<td>LD44.M</td>
</tr>
<tr>
<td>604</td>
<td>Deletions of the long arm of chromosome 18</td>
<td>LD44.J0</td>
</tr>
<tr>
<td>605</td>
<td>Duplications of the long arm of chromosome 8</td>
<td>LD41.70</td>
</tr>
<tr>
<td>606</td>
<td>Q fever</td>
<td>1C33</td>
</tr>
<tr>
<td>607</td>
<td>Deletions of the long arm of chromosome 2</td>
<td>LD44.20</td>
</tr>
<tr>
<td>608</td>
<td>Deletions of the long arm of chromosome 1</td>
<td>LD44.10</td>
</tr>
<tr>
<td>609</td>
<td>Other specified chromosomal anomalies, excluding gene mutations</td>
<td>LD7Y</td>
</tr>
<tr>
<td>610</td>
<td>Other specified syndromic genetic deafness</td>
<td>LD2H.Y</td>
</tr>
<tr>
<td>611</td>
<td>Deletions of the long arm of chromosome 3</td>
<td>LD44.30</td>
</tr>
<tr>
<td>612</td>
<td>Duplications of the long arm of chromosome 1</td>
<td>LD41.00</td>
</tr>
<tr>
<td>613</td>
<td>Deletions of the long arm of chromosome 4</td>
<td>LD44.40</td>
</tr>
<tr>
<td>614</td>
<td>Deletions of the long arm of chromosome 12</td>
<td>LD44.C0</td>
</tr>
<tr>
<td>615</td>
<td>Deletions of the long arm of chromosome 17</td>
<td>LD44.H0</td>
</tr>
<tr>
<td>616</td>
<td>Other specified syndromes with multiple structural anomalies, not of environmental origin</td>
<td>LD2F.1Y</td>
</tr>
<tr>
<td>617</td>
<td>Deletions of chromosome 14</td>
<td>LD44.E</td>
</tr>
<tr>
<td>618</td>
<td>Acromesomelic dysplasias</td>
<td>LD24.9</td>
</tr>
<tr>
<td>619</td>
<td>Deletions of the long arm of chromosome 6</td>
<td>LD44.60</td>
</tr>
<tr>
<td>620</td>
<td>Deletions of the long arm of chromosome 20</td>
<td>LD44.L0</td>
</tr>
<tr>
<td>621</td>
<td>Recessive limb-girdle muscular dystrophy</td>
<td>8C70.41</td>
</tr>
<tr>
<td>622</td>
<td>Deletions of the long arm of chromosome 5</td>
<td>LD44.50</td>
</tr>
<tr>
<td>623</td>
<td>Other specified deletions of chromosome 22</td>
<td>LD44.NY</td>
</tr>
<tr>
<td>624</td>
<td>Duplications of the long arm of chromosome 5</td>
<td>LD41.40</td>
</tr>
<tr>
<td>625</td>
<td>Duplications of the long arm of chromosome 3</td>
<td>LD41.20</td>
</tr>
<tr>
<td>626</td>
<td>Deletions of chromosome 15</td>
<td>LD44.F</td>
</tr>
<tr>
<td>627</td>
<td>Duplications of the long arm of chromosome 17</td>
<td>LD41.G0</td>
</tr>
<tr>
<td>628</td>
<td>Duplications of the long arm of chromosome 10</td>
<td>LD41.90</td>
</tr>
<tr>
<td>629</td>
<td>Deletions of chromosome 13</td>
<td>LD44.D</td>
</tr>
<tr>
<td>630</td>
<td>Duplications of the long arm of chromosome 19</td>
<td>LD41.J0</td>
</tr>
<tr>
<td>631</td>
<td>Syndromes with obesity as a major feature</td>
<td>LD29</td>
</tr>
<tr>
<td>632</td>
<td>Duplications of the long arm of chromosome 4</td>
<td>LD41.30</td>
</tr>
<tr>
<td>633</td>
<td>Deletions of the long arm of chromosome 10</td>
<td>LD44.A0</td>
</tr>
<tr>
<td>634</td>
<td>Deletions of the long arm of chromosome 7</td>
<td>LD44.70</td>
</tr>
<tr>
<td>635</td>
<td>CATCH 22 phenotype</td>
<td>LD44.N0</td>
</tr>
<tr>
<td>636</td>
<td>Deletions of the long arm of chromosome 9</td>
<td>LD44.90</td>
</tr>
<tr>
<td>637</td>
<td>Duplications of the long arm of chromosome 6</td>
<td>LD41.50</td>
</tr>
<tr>
<td>638</td>
<td>Duplications of the long arm of chromosome 9</td>
<td>LD41.80</td>
</tr>
<tr>
<td>639</td>
<td>Duplications of the long arm of chromosome 20</td>
<td>LD41.K0</td>
</tr>
<tr>
<td>640</td>
<td>Duplications of chromosome 15</td>
<td>LD41.E</td>
</tr>
<tr>
<td>641</td>
<td>Duplications of chromosome 13</td>
<td>LD41.C</td>
</tr>
<tr>
<td>642</td>
<td>Coenzyme Q10 deficiency</td>
<td>5C53.22</td>
</tr>
<tr>
<td>643</td>
<td>Duplications of the long arm of chromosome 18</td>
<td>LD41.H0</td>
</tr>
<tr>
<td>644</td>
<td>Duplications of the long arm of chromosome 16</td>
<td>LD41.F0</td>
</tr>
<tr>
<td>645</td>
<td>Duplications of the long arm of chromosome 2</td>
<td>LD41.10</td>
</tr>
<tr>
<td>646</td>
<td>Duplications of chromosome 14</td>
<td>LD41.D</td>
</tr>
<tr>
<td>647</td>
<td>Deletions of the long arm of chromosome 8</td>
<td>LD44.80</td>
</tr>
<tr>
<td>648</td>
<td>Other specified syndromic craniosynostoses</td>
<td>LD24.GY</td>
</tr>
<tr>
<td>649</td>
<td>Deletions of the long arm of chromosome 11</td>
<td>LD44.B0</td>
</tr>
<tr>
<td>650</td>
<td>Duplications of chromosome 22</td>
<td>LD41.M</td>
</tr>
<tr>
<td>651</td>
<td>Deletions of the long arm of chromosome 16</td>
<td>LD44.G0</td>
</tr>
<tr>
<td>652</td>
<td>Other specified periodontal disease</td>
<td>DA0C.Y</td>
</tr>
<tr>
<td>653</td>
<td>Disorders of cobalamin metabolism or transport</td>
<td>5C63.0</td>
</tr>
<tr>
<td>654</td>
<td>Other specified obesity</td>
<td>5B81.Y</td>
</tr>
<tr>
<td>655</td>
<td>Constitutional neutrophilia</td>
<td>4B00.10</td>
</tr>
<tr>
<td>656</td>
<td>Constitutional neutropaenia</td>
<td>4B00.00</td>
</tr>
<tr>
<td>657</td>
<td>Immunodeficiency with an early component of complement deficiency</td>
<td>4A00.10</td>
</tr>
<tr>
<td>658</td>
<td>Primary inherited erythrocytosis</td>
<td>3A80.0</td>
</tr>
<tr>
<td>659</td>
<td>Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associated</td>
<td>2A90.5</td>
</tr>
<tr>
<td>660</td>
<td>Type 2 diabetes mellitus</td>
<td>5A11</td>
</tr>
<tr>
<td>661</td>
<td>Type 1 diabetes mellitus</td>
<td>5A10</td>
</tr>
<tr>
<td>662</td>
<td>Sick-euthyroid syndrome</td>
<td>5A06</td>
</tr>
<tr>
<td>663</td>
<td>Abnormalities of size or form of teeth</td>
<td>LA30.4</td>
</tr>
<tr>
<td>664</td>
<td>Disorders of protein N-glycosylation</td>
<td>5C54.0</td>
</tr>
<tr>
<td>665</td>
<td>Mature T-cell or NK-cell neoplasms, unspecified</td>
<td>2B2Z</td>
</tr>
<tr>
<td>666</td>
<td>Enteropathy associated T-cell lymphoma</td>
<td>2A90.7</td>
</tr>
<tr>
<td>667</td>
<td>Peripheral T-cell lymphoma, not otherwise specified</td>
<td>2A90.C</td>
</tr>
<tr>
<td>668</td>
<td>Other specified mature T-cell or NK-cell neoplasms</td>
<td>2B2Y</td>
</tr>
<tr>
<td>669</td>
<td>Severe combined immunodeficiencies</td>
<td>4A01.10</td>
</tr>
<tr>
<td>670</td>
<td>Brown-Sequard syndrome at T2 level</td>
<td>NA91.4&amp;XA6GU9</td>
</tr>
<tr>
<td>671</td>
<td>Brown-Sequard syndrome at T1 level</td>
<td>NA91.4&amp;XA17G6</td>
</tr>
<tr>
<td>672</td>
<td>Fracture of thoracic vertebra</td>
<td>NA82.0</td>
</tr>
<tr>
<td>673</td>
<td>Precursor T-lymphoblastic neoplasms</td>
<td>2A71</td>
</tr>
<tr>
<td>674</td>
<td>Brown-Sequard syndrome at T3 level</td>
<td>NA91.4&amp;XA7U15</td>
</tr>
<tr>
<td>675</td>
<td>Acquired neutropaenia</td>
<td>4B00.01</td>
</tr>
<tr>
<td>676</td>
<td>Brown-Sequard syndrome at T4 level</td>
<td>NA91.4&amp;XA5UF4</td>
</tr>
<tr>
<td>677</td>
<td>Brown-Sequard syndrome at T5 level</td>
<td>NA91.4&amp;XA0D58</td>
</tr>
<tr>
<td>678</td>
<td>Combined immunodeficiencies, unspecified</td>
<td>4A01.1Z</td>
</tr>
<tr>
<td>679</td>
<td>Brown-Sequard syndrome at T6 level</td>
<td>NA91.4&amp;XA5Q83</td>
</tr>
<tr>
<td>680</td>
<td>Primary cutaneous CD30-positive T-cell lymphoproliferative disorders</td>
<td>2B03</td>
</tr>
<tr>
<td>681</td>
<td>Brown-Sequard syndrome at T12 level</td>
<td>NA91.4&amp;XA6FB9</td>
</tr>
<tr>
<td>682</td>
<td>Primary cutaneous T-cell lymphoma of undetermined or unspecified type</td>
<td>2B0Z</td>
</tr>
<tr>
<td>683</td>
<td>Brown-Sequard syndrome at T10 level</td>
<td>NA91.4&amp;XA4QU1</td>
</tr>
<tr>
<td>684</td>
<td>Brown-Sequard syndrome at T7 level</td>
<td>NA91.4&amp;XA79E1</td>
</tr>
<tr>
<td>685</td>
<td>Brown-Sequard syndrome at T8 level</td>
<td>NA91.4&amp;XA0N76</td>
</tr>
<tr>
<td>686</td>
<td>Brown-Sequard syndrome at T11 level</td>
<td>NA91.4&amp;XA9DV3</td>
</tr>
<tr>
<td>687</td>
<td>Brown-Sequard syndrome at T9 level</td>
<td>NA91.4&amp;XA5T86</td>
</tr>
<tr>
<td>688</td>
<td>Fracture of lower end of humerus, unspecified</td>
<td>NC12.4Z</td>
</tr>
<tr>
<td>689</td>
<td>Mycosis fungoides</td>
<td>2B01</td>
</tr>
<tr>
<td>690</td>
<td>Paucibacillary leprosy</td>
<td>1B20.0</td>
</tr>
<tr>
<td>691</td>
<td>T-cell prolymphocytic leukaemia</td>
<td>2A90.0</td>
</tr>
<tr>
<td>692</td>
<td>Systemic Epstein-Barr Virus-positive T-cell lymphoma of childhood</td>
<td>2A90.4</td>
</tr>
<tr>
<td>693</td>
<td>T-cell lymphoma of small intestine</td>
<td>2B33.5&amp;XH3HJ2&amp;XA6452</td>
</tr>
<tr>
<td>694</td>
<td>Central cord syndrome of thoracic spinal cord at T2 level</td>
<td>NA91.1&amp;XA6GU9</td>
</tr>
<tr>
<td>695</td>
<td>Dislocation of thoracic vertebra</td>
<td>NA83.1</td>
</tr>
<tr>
<td>696</td>
<td>Anterior cord syndrome of thoracic spinal cord at T2 level</td>
<td>NA91.2&amp;XA6GU9</td>
</tr>
<tr>
<td>697</td>
<td>Central cord syndrome of thoracic spinal cord at T1 level</td>
<td>NA91.1&amp;XA17G6</td>
</tr>
<tr>
<td>698</td>
<td>Posterior cord syndrome of thoracic spinal cord at T2 level</td>
<td>NA91.3&amp;XA6GU9</td>
</tr>
<tr>
<td>699</td>
<td>Mature T-cell lymphoma, specified types, nodal or systemic</td>
<td>2A90</td>
</tr>
<tr>
<td>700</td>
<td>Anterior cord syndrome of thoracic spinal cord at T1 level</td>
<td>NA91.2&amp;XA17G6</td>
</tr>
<tr>
<td>701</td>
<td>Posterior cord syndrome of thoracic spinal cord at T1 level</td>
<td>NA91.3&amp;XA17G6</td>
</tr>
<tr>
<td>702</td>
<td>Central cord syndrome of thoracic spinal cord at T3 level</td>
<td>NA91.1&amp;XA7U15</td>
</tr>
<tr>
<td>703</td>
<td>Anterior cord syndrome of thoracic spinal cord at T3 level</td>
<td>NA91.2&amp;XA7U15</td>
</tr>
<tr>
<td>704</td>
<td>Posterior cord syndrome of thoracic spinal cord at T3 level</td>
<td>NA91.3&amp;XA7U15</td>
</tr>
<tr>
<td>705</td>
<td>Central cord syndrome of thoracic spinal cord at T4 level</td>
<td>NA91.1&amp;XA5UF4</td>
</tr>
<tr>
<td>706</td>
<td>Central cord syndrome of thoracic spinal cord at T5 level</td>
<td>NA91.1&amp;XA0D58</td>
</tr>
<tr>
<td>707</td>
<td>Anterior cord syndrome of thoracic spinal cord at T4 level</td>
<td>NA91.2&amp;XA5UF4</td>
</tr>
<tr>
<td>708</td>
<td>Anterior cord syndrome of thoracic spinal cord at T5 level</td>
<td>NA91.2&amp;XA0D58</td>
</tr>
<tr>
<td>709</td>
<td>Irritable bowel syndrome, unsubtyped</td>
<td>DD91.03</td>
</tr>
<tr>
<td>710</td>
<td>DNA repair defects other than combined T-cell or B-cell immunodeficiencies</td>
<td>4A01.31</td>
</tr>
<tr>
<td>711</td>
<td>Other inherited coagulation factor deficiency with bleeding tendency, unspecified</td>
<td>3B14.Z</td>
</tr>
<tr>
<td>712</td>
<td>Chronic kidney disease, stage 5</td>
<td>GB61.5</td>
</tr>
<tr>
<td>713</td>
<td>Other specified haemorrhagic diseases due to acquired coagulation factor defects</td>
<td>3B2Y</td>
</tr>
<tr>
<td>714</td>
<td>Alpha-granule diseases</td>
<td>3B62.00</td>
</tr>
<tr>
<td>715</td>
<td>Other specified disorders of mitochondrial oxidative phosphorylation</td>
<td>5C53.2Y</td>
</tr>
<tr>
<td>716</td>
<td>Hereditary sensory and autonomic neuropathy type V</td>
<td>8C21.3</td>
</tr>
<tr>
<td>717</td>
<td>Disorders of multiple glycosylation or other pathways</td>
<td>5C54.2</td>
</tr>
<tr>
<td>718</td>
<td>Exotropia</td>
<td>9C80.1</td>
</tr>
<tr>
<td>719</td>
<td>Esotropia</td>
<td>9C80.0</td>
</tr>
<tr>
<td>720</td>
<td>Pityriasis rubra pilaris</td>
<td>EA94</td>
</tr>
<tr>
<td>721</td>
<td>Other specified hereditary thrombophilia</td>
<td>3B61.0Y</td>
</tr>
<tr>
<td>722</td>
<td>Choledochal cyst</td>
<td>LB20.20</td>
</tr>
<tr>
<td>723</td>
<td>Acute leukaemias of ambiguous lineage</td>
<td>2A61</td>
</tr>
<tr>
<td>724</td>
<td>Other B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities</td>
<td>2A70.Y</td>
</tr>
<tr>
<td>725</td>
<td>Turner syndrome</td>
<td>LD50.0</td>
</tr>
<tr>
<td>726</td>
<td>Langerhans cell histiocytosis, unspecified</td>
<td>2B31.2Z</td>
</tr>
<tr>
<td>727</td>
<td>Other specified conditions with disorders of intellectual development as a relevant clinical feature</td>
<td>LD90.Y</td>
</tr>
<tr>
<td>728</td>
<td>Karyotype 47,XXX</td>
<td>LD50.1</td>
</tr>
<tr>
<td>729</td>
<td>Hereditary factor X deficiency</td>
<td>3B14.1</td>
</tr>
<tr>
<td>730</td>
<td>Other specified number anomalies of chromosome X</td>
<td>LD50.Y</td>
</tr>
<tr>
<td>731</td>
<td>Fragile X chromosome</td>
<td>LD55</td>
</tr>
<tr>
<td>732</td>
<td>Murray Valley encephalitis</td>
<td>1C88</td>
</tr>
<tr>
<td>733</td>
<td>X-linked ichthyosis</td>
<td>EC20.01</td>
</tr>
<tr>
<td>734</td>
<td>Coronary microvascular disease</td>
<td>BA86</td>
</tr>
<tr>
<td>735</td>
<td>Erythropoietic porphyrias</td>
<td>5C58.12</td>
</tr>
<tr>
<td>736</td>
<td>Syndromic ichthyosis</td>
<td>LD27.2</td>
</tr>
<tr>
<td>737</td>
<td>Number anomalies of chromosome X, unspecified</td>
<td>LD50.Z</td>
</tr>
<tr>
<td>738</td>
<td>Langerhans cell histiocytosis involving the skin</td>
<td>2B31.20</td>
</tr>
<tr>
<td>739</td>
<td>Fabry disease</td>
<td>5C56.01</td>
</tr>
<tr>
<td>740</td>
<td>Other specified syndromic genetic deafness</td>
<td>LD2H.Y</td>
</tr>
<tr>
<td>741</td>
<td>Karyotype 45, X</td>
<td>LD50.00</td>
</tr>
<tr>
<td>742</td>
<td>Other specified immunodeficiencies with predominantly antibody defects</td>
<td>4A01.0Y</td>
</tr>
<tr>
<td>743</td>
<td>Special screening examination for neoplasm of breast</td>
<td>QA09.3</td>
</tr>
<tr>
<td>744</td>
<td>Genetically-determined cutis laxa</td>
<td>LD28.2</td>
</tr>
<tr>
<td>745</td>
<td>Disorders of creatine metabolism</td>
<td>5C53.4</td>
</tr>
<tr>
<td>746</td>
<td>Localised spinal muscular atrophy</td>
<td>8B61.4</td>
</tr>
<tr>
<td>747</td>
<td>Hypophosphataemic rickets</td>
<td>5C63.22</td>
</tr>
<tr>
<td>748</td>
<td>Other specified hereditary ataxia</td>
<td>8A03.1Y</td>
</tr>
<tr>
<td>749</td>
<td>Other specified congenital hypothyroidism</td>
<td>5A00.0Y</td>
</tr>
<tr>
<td>750</td>
<td>Other specified types of Ehlers-Danlos syndrome</td>
<td>LD28.1Y</td>
</tr>
<tr>
<td>751</td>
<td>Radiological examination</td>
<td>QA00.B</td>
</tr>
<tr>
<td>752</td>
<td>Nephrogenic diabetes insipidus</td>
<td>GB90.4A</td>
</tr>
<tr>
<td>753</td>
<td>Dementia due to other specified diseases classified elsewhere</td>
<td>6D85.Y</td>
</tr>
<tr>
<td>754</td>
<td>Uniparental disomies of maternal origin</td>
<td>LD45.0</td>
</tr>
<tr>
<td>755</td>
<td>Harmful effects of drugs, medicaments or biological substances, not elsewhere classified</td>
<td>NE60</td>
</tr>
<tr>
<td>756</td>
<td>Immune dysregulation syndromes presenting primarily with lymphoproliferation</td>
<td>4A01.22</td>
</tr>
<tr>
<td>757</td>
<td>Other specified combined immunodeficiencies</td>
<td>4A01.1Y</td>
</tr>
<tr>
<td>758</td>
<td>Hypohidrotic ectodermal dysplasia</td>
<td>LD27.02</td>
</tr>
<tr>
<td>759</td>
<td>Arthrogryposis multiplex congenita</td>
<td>LD26.41</td>
</tr>
<tr>
<td>760</td>
<td>Acrofacial dysostoses</td>
<td>LD25.2</td>
</tr>
<tr>
<td>761</td>
<td>Uniparental disomies of paternal origin</td>
<td>LD45.1</td>
</tr>
<tr>
<td>762</td>
<td>Mosaicism, 45, X, 46, XX or XY</td>
<td>LD50.03</td>
</tr>
<tr>
<td>763</td>
<td>Mosaicism, lines with various numbers of X chromosomes</td>
<td>LD50.2</td>
</tr>
<tr>
<td>764</td>
<td>Congenital adrenal hypoplasia</td>
<td>LC80</td>
</tr>
<tr>
<td>765</td>
<td>Congenital thrombocytosis</td>
<td>3B63.0</td>
</tr>
<tr>
<td>766</td>
<td>Other specified syndromes with central nervous system anomalies as a major feature</td>
<td>LD20.Y</td>
</tr>
<tr>
<td>767</td>
<td>Dystonia associated with heredodegenerative disorders</td>
<td>8A02.12</td>
</tr>
<tr>
<td>768</td>
<td>Lesch-Nyhan syndrome</td>
<td>5C55.01</td>
</tr>
<tr>
<td>769</td>
<td>Other specified hypoparathyroidism due to impaired parathyroid hormone secretion</td>
<td>5A50.0Y</td>
</tr>
<tr>
<td>770</td>
<td>Emery-Dreifuss muscular dystrophy</td>
<td>8C70.2</td>
</tr>
<tr>
<td>771</td>
<td>Juvenile retinoschisis</td>
<td>9B73.11</td>
</tr>
<tr>
<td>772</td>
<td>Klinefelter syndrome, male with more than two X chromosomes</td>
<td>LD50.31</td>
</tr>
<tr>
<td>773</td>
<td>Structural anomalies of chromosome X, excluding Turner syndrome</td>
<td>LD51</td>
</tr>
<tr>
<td>774</td>
<td>Centronuclear myopathy</td>
<td>8C72.01</td>
</tr>
<tr>
<td>775</td>
<td>Male with double or multiple Y</td>
<td>LD52.1</td>
</tr>
<tr>
<td>776</td>
<td>Structural anomalies of chromosome Y</td>
<td>LD53</td>
</tr>
<tr>
<td>777</td>
<td>Testicular hypofunction</td>
<td>5A81.1</td>
</tr>
<tr>
<td>778</td>
<td>Number anomalies of chromosome Y, unspecified</td>
<td>LD52.Z</td>
</tr>
<tr>
<td>779</td>
<td>Other specified number anomalies of chromosome Y</td>
<td>LD52.Y</td>
</tr>
<tr>
<td>780</td>
<td>Congenital cataract</td>
<td>LA12.1</td>
</tr>
<tr>
<td>781</td>
<td>Iron overload diseases</td>
<td>5C64.10</td>
</tr>
<tr>
<td>782</td>
<td>Other specified qualitative platelet defects</td>
<td>3B62.Y</td>
</tr>
<tr>
<td>783</td>
<td>Noncompaction cardiomyopathy</td>
<td>BC44</td>
</tr>
<tr>
<td>784</td>
<td>Myofibrillar myopathy</td>
<td>8C76</td>
</tr>
</tbody></table>

  

</body></html>